Vascular endothelial growth factor (VEGF) inhibitor, Eydenzelt (aflibercept-boav), is now approved to treat retinal disease ...
Pharmaceutical Technology on MSN
FDA approves Celltrion’s Eydenzelt for eye diseases
Eydenzelt is a vascular endothelial growth factor inhibitor referencing Eylea, which is jointly developed by Regeneron ...
REGENXBIO completed enrollment in its ATMOSPHERE and ASCENT trials that will be evaluating surabgene lomparvovec (sura-vec, ...
The Food and Drug Administration (FDA) has approved Eydenzelt ® (aflibercept-boav), a biosimilar to Eylea ® (aflibercept).
Zacks Investment Research on MSN
Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo
Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has approved the label expansion of PD-1 inhibitor Libtayo ...
Light responsive nanomotors dissolve blood clots and repair vessel tissue by combining catalytic activity, targeted motion, ...
An mRNA vaccine developed by researchers from Japan suppressed abnormal blood vessel growth or neovascularization in the ...
New research links TGF-β1 to maladaptive bone marrow endothelial cell repair and shows that blocking its pathway can restore haematopoietic function after transplant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback